79 related articles for article (PubMed ID: 18162214)
21. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
[TBL] [Abstract][Full Text] [Related]
22. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
Libert D; Yuan CM; Masih KE; Galera P; Salem D; Shalabi H; Yates B; Delbrook C; Shern JF; Fry TJ; Khan J; Stetler-Stevenson M; Shah NN
Leukemia; 2020 Nov; 34(11):3064-3069. PubMed ID: 32103145
[No Abstract] [Full Text] [Related]
23. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
[TBL] [Abstract][Full Text] [Related]
24. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
[TBL] [Abstract][Full Text] [Related]
25. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
Bremer E; ten Cate B; Samplonius DF; Mueller N; Wajant H; Stel AJ; Chamuleau M; van de Loosdrecht AA; Stieglmaier J; Fey GH; Helfrich W
Cancer Res; 2008 Jan; 68(2):597-604. PubMed ID: 18199557
[TBL] [Abstract][Full Text] [Related]
26. Adoptive transfer of double negative T regulatory cells induces B-cell death in vivo and alters rejection pattern of rat-to-mouse heart transplantation.
Ma Y; He KM; Garcia B; Min W; Jevnikar A; Zhang ZX
Xenotransplantation; 2008 Feb; 15(1):56-63. PubMed ID: 18333914
[TBL] [Abstract][Full Text] [Related]
27. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
28. CD22 is not expressed merely on B cells: comment on the article by Vos et al.
Teng YK; Engels MC; van Laar JM
Arthritis Rheum; 2008 Mar; 58(3):911-2; author reply 912-3. PubMed ID: 18311823
[No Abstract] [Full Text] [Related]
29. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.
Ayuk F; Zander A; Kröger N
Ann Hematol; 2009 May; 88(5):401-4. PubMed ID: 19172273
[TBL] [Abstract][Full Text] [Related]
31. Advances in AML immunotherapy: the case for T-bodies.
Suh DY; Frankel AE
Leuk Res; 2007 Feb; 31(2):127-8. PubMed ID: 17137625
[No Abstract] [Full Text] [Related]
32. [Possibility of selective induction of a GVL effect without increasing GVHD].
Akatsuka Y
Rinsho Ketsueki; 2008 Aug; 49(8):607-15. PubMed ID: 18800609
[No Abstract] [Full Text] [Related]
33. T-cell therapy extends cancer survival to years.
Ledford H
Nature; 2014 Dec; 516(7530):156. PubMed ID: 25503214
[No Abstract] [Full Text] [Related]
34. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants.
Michonneau D; Peffault de Latour R; Porcher R; Robin M; Benbunan M; Rocha V; Ribaud P; Ferry C; Devergie A; Vanneaux V; Gluckman E; Marolleau JP; Socié G; Larghero J
Br J Haematol; 2009 Apr; 145(1):107-14. PubMed ID: 19183190
[TBL] [Abstract][Full Text] [Related]
35. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
36. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
37. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
38. B cell neoplasms.
Skoog L; Tani E
Monogr Clin Cytol; 2009; 18():19-37. PubMed ID: 19092260
[No Abstract] [Full Text] [Related]
39. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
40. Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects.
Banovic T; MacDonald KP; Markey KA; Morris ES; Kuns RD; Varelias A; Hill GR
Biol Blood Marrow Transplant; 2009 Jan; 15(1):126-30. PubMed ID: 19135951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
